4,625 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) Bought by Haven Capital Group Inc.

Haven Capital Group Inc. purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 4,625 shares of the biopharmaceutical company's stock, valued at approximately $427,000.

A number of other hedge funds and other institutional investors also recently bought and sold shares of GILD. Swedbank AB boosted its stake in Gilead Sciences by 10.2% in the third quarter. Swedbank AB now owns 2,047,609 shares of the biopharmaceutical company's stock valued at $171,672,000 after acquiring an additional 189,622 shares during the period. Natixis Advisors LLC boosted its stake in Gilead Sciences by 18.1% in the third quarter. Natixis Advisors LLC now owns 169,363 shares of the biopharmaceutical company's stock valued at $14,199,000 after acquiring an additional 25,912 shares during the period. Claro Advisors LLC boosted its stake in Gilead Sciences by 16.1% in the third quarter. Claro Advisors LLC now owns 8,555 shares of the biopharmaceutical company's stock valued at $717,000 after acquiring an additional 1,187 shares during the period. TrinityPoint Wealth LLC boosted its stake in Gilead Sciences by 658.5% in the third quarter. TrinityPoint Wealth LLC now owns 43,606 shares of the biopharmaceutical company's stock valued at $3,656,000 after acquiring an additional 37,857 shares during the period. Finally, Aljian Capital Management LLC acquired a new position in Gilead Sciences in the third quarter valued at approximately $479,000. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 1.1 %

NASDAQ:GILD traded up $1.21 during trading hours on Friday, hitting $107.08. 26,496,292 shares of the stock traded hands, compared to its average volume of 6,797,069. The firm has a 50 day moving average price of $103.68 and a 200 day moving average price of $93.75. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $119.96. The firm has a market cap of $133.35 billion, a price-to-earnings ratio of 289.41, a PEG ratio of 0.71 and a beta of 0.21.

Remove Ads

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. Equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, March 28th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a boost from Gilead Sciences's previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a dividend yield of 2.95%. The ex-dividend date of this dividend is Friday, March 14th. Gilead Sciences's payout ratio is currently 854.05%.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 17,929 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $118.17, for a total transaction of $2,118,669.93. Following the transaction, the chief financial officer now directly owns 169,061 shares in the company, valued at $19,977,938.37. The trade was a 9.59 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 302,785 shares of company stock worth $30,503,250 in the last ninety days. Corporate insiders own 0.29% of the company's stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on the company. Morgan Stanley boosted their price objective on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 11th. Oppenheimer boosted their price objective on Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research report on Tuesday, March 4th. The Goldman Sachs Group boosted their price objective on Gilead Sciences from $85.00 to $96.00 and gave the stock a "neutral" rating in a research report on Wednesday, February 12th. DZ Bank upgraded Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective for the company in a research report on Thursday, February 13th. Finally, JPMorgan Chase & Co. boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an "overweight" rating in a research report on Wednesday, January 29th. Eleven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the company's stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $104.52.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.